Mai-Lis Hellenius
Stockholm, Sweden
Mai-Lis Hellénius, MD, Ph.D., professor in cardiovascular prevention at the Karolinska Institutet, Stockholm, Sweden.
Mai-Lis Hellénius was born 1953. MD at Karolinska Institutet 1978. Certified specialist in Family Medicine 1985. In 1995 Mai-Lis Hellénius defended her thesis “Prevention of cardiovascular disease – Studies on the role of diet and exercise in the prevention of cardiovascular disease among middle aged men.” The thesis was based on a controlled randomized trial and thereby she was among the first in the world to scientifically evaluate advice on lifestyle. Associate professor in 1999. Professor in cardiovascular prevention focusing lifestyle in 2006.
She has for more than 40 years been working both as a clinician, a researcher and a teacher in the area of lifestyle medicine. She was among the first physicians in the world initiating physical activity on prescription in 1987. Mai-Lis Hellénius has 260 publications and 169 of them are publications in peer review journals.
Mai-Lis Hellénius has been the tutor of 16 Ph.D. students who have defended their thesis. All Ph.D. projects have focused physical activity, lifestyle and prevention. She has been engaged in the writing of national and Nordic guidelines for diet and physical activity as well as prevention of cardiovascular disease. She is a member of many expert committees both nationally and internationally and she has been invited speaker at international meetings more than 100 times. Mai-Lis Hellenius has served as a faculty opponent on 36 occasions of both Swedish and international universities. She has been awarded in Sweden and from several international universities. Year 2017 she was invited to give the Morris-Paffenbarger Honorary lecture at the opening session of American College of Sports Medicine meeting in Denver, USA.
She has written several textbooks in lifestyle medicine and cardiovascular prevention for the professional audience. She has also developed a web-based educational program for health care professionals as well as the public, which was launched in 2009 from the Karolinska Institutet (www.sundkurs.se). She is a requested lecturer for professional as well as for the public.
Mai-Lis Hellénius has also written several popular science books on nutrition, physical activity and a healthy lifestyle. Several of them have been awarded in Sweden and internationally. Mai-Lis Hellénius received the Dun Gifford’s Award from Gourmand International Cookbook Awards for one of the books. The books “Vitally important” about lifestyle and health and Vitally important-the Cookbook, won the Gourmand International Cookbook Award in 2017 and 2019. In 2021 the book Vitally important was awarded as the Best during 25 years in its category and a new book about health for seniors also won a prize the Gourmand Cookbook International Award.
Tuesday 24 May
Physical activity end cardiovascular prevention
-
Kausik Ray
Kausik Ray
London, United KingdomKausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials –Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a post-doctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President of the European Atherosclerosis Society, also serving on the EAS Consensus panel and EAS Executive Committee. Professor Ray has either been the National Lead Investigator, Principal Investigator, or served on committees for several major medical trials, as well as international registries and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1, 3, 11 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 87, an i10 of 220 and over 92,000 citations for his work in journals such as New England Journal of Medicine, The Lancet, JAMA, European Heart Journal, Circulation and JACC. He has also been included in the Clarivate Analytics’ list of the top 1% most cited authors in all of global medicine in 2018, 2019 and 2020. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH which includes 70 countries and 62,000 cases, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London. -
Joseph Saseen
Joseph Saseen
Aurora, USAJoseph Saseen, PharmD, is Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and a Professor of Family Medicine. He also served as Vice Chair of the Department of Clinical Pharmacy for 10 years.
Dr. Saseen is President of the National Lipid Association (NLA). He is a fellow of the American College of Clinical Pharmacy, American Society of Health-system Pharmacists, American Pharmacists Association, the American Heart Association, and the NLA. He is board certified as a Pharmacotherapy Specialist and an Ambulatory Care Pharmacists, and is a certified as a Clinical Lipid Specialist.
Dr. Saseen has responsibilities for enhancing the school’s clinical enterprise, further developing sustainable clinical service models, and advocating for advancing the practice of pharmacy in the State of Colorado. He is a clinical pharmacist at the University of Colorado Health focusing on cardiovascular risk reduction and population health. Dr. Saseen teaches cardiovascular pharmacotherapy and other topics related to primary care, and is the PGY2 Ambulatory Care residency program director. His scholarly work includes almost 200 peer-reviewed publications and book chapters.
